Hikma Pharmaceuticals Plc (HIK) Upgraded to Buy by Numis Securities Ltd

Numis Securities Ltd upgraded shares of Hikma Pharmaceuticals Plc (LON:HIK) to a buy rating in a research note issued to investors on Thursday morning. They currently have GBX 1,300 ($17.10) target price on the stock.

A number of other equities analysts also recently weighed in on HIK. Jefferies Group LLC restated a hold rating and issued a GBX 1,045 ($13.74) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday. J P Morgan Chase & Co restated a neutral rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, September 29th. Citigroup Inc. restated a neutral rating and issued a GBX 1,350 ($17.76) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 24th. Barclays PLC cut their target price on Hikma Pharmaceuticals Plc from GBX 2,200 ($28.94) to GBX 1,500 ($19.73) and set an overweight rating on the stock in a research note on Friday, August 25th. Finally, Peel Hunt restated a hold rating and issued a GBX 2,150 ($28.28) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and a consensus target price of GBX 1,321.91 ($17.39).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down GBX 17.04 ($0.22) during midday trading on Thursday, hitting GBX 981.46 ($12.91). The stock had a trading volume of 2,310,000 shares, compared to its average volume of 823,245. Hikma Pharmaceuticals Plc has a 12-month low of GBX 934 ($12.28) and a 12-month high of GBX 2,346 ($30.86).

TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/11/hikma-pharmaceuticals-plc-hik-upgraded-to-buy-by-numis-securities-ltd.html.

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply